2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
This guideline cites 6 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2021
- Source
- Gulati M, Levy PD, et al. Circulation. 2021;144(22):e368–e454.doi 10.1161/CIR.0000000000001029
The ESC has no stand-alone chest-pain guideline — the topic is folded into the chronic coronary syndrome document — which makes this the reference text on both sides of the Atlantic for the diagnostic pathway itself. It retires the word 'atypical' in favour of 'cardiac, possible cardiac or non-cardiac', makes high-sensitivity troponin within a structured clinical decision pathway the preferred rule-out, and puts coronary CT angiography first-line in intermediate-risk patients without known coronary disease, with FFR-CT for intermediate stenoses. Deliberately, it also states where no testing is needed at all. The register's imaging and downstream-management trials are grouped below.
Anatomical testing: coronary CT angiography1
- 2018SCOT-HEARTCardiology · Coronary · CT coronary angiographyIn 4,146 patients with stable chest pain, adding CT coronary angiography reduced 5-year coronary death or non-fatal MI compared with standard care alone.HR 0.5995% CI 0.41-0.84Read →
Physiological assessment of stenoses (FFR / FFR-CT)2
- 2012FAME 2Cardiology · Coronary · FFR-guided PCIIn 888 patients with stable coronary disease and a functionally significant (FFR ≤0.80) stenosis, FFR-guided PCI plus medical therapy reduced death, MI, or urgent revascularisation compared with medical therapy alone.HR 0.3295% CI 0.19-0.53Read →
- 2009FAMECardiology · Coronary · RevascularisationIn 1,005 patients with multivessel CAD, FFR-guided PCI reduced MACE at one year versus angiography-guided PCI.13.2% vs 18.3%Read →
What follows the diagnosis: revascularisation vs. medical therapy3
- 2020ISCHEMIA CoreCardiology · Coronary · RevascularisationIn 5,179 patients with stable CAD and moderate-to-severe ischaemia, an initial invasive strategy did not reduce CV death, MI, hospitalisation for unstable angina, HF or resuscitated arrest compared with an initial conservative strategy.HR 0.93Read →
- 2018ORBITACardiology · Coronary · RevascularisationIn 200 patients with stable single-vessel angina, PCI did not improve exercise time at 6 weeks compared with a sham procedure.Read →
- 2007COURAGECardiology · Coronary · RevascularisationIn 2,287 patients with stable coronary artery disease, PCI added to optimal medical therapy did not reduce death or non-fatal MI compared with optimal medical therapy alone.HR 1.05Read →
Published since the guideline1
- 2023ORBITA-2Cardiology · Coronary · RevascularisationIn 301 patients with stable angina on no antianginal medication, PCI improved the angina symptom score compared with a placebo procedure.OR 2.21Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2015PROMISE
Anatomical vs. functional first-line testing in stable chest pain.
- 2012ROMICAT-II
Coronary CT angiography in the emergency department.
- 2012ACRIN-PA
CT angiography for low-to-intermediate-risk acute chest pain.
- 2015PLATFORM
FFR-CT reduced invasive angiography without obstructive disease.
- 2018High-STEACS
Implementation of a high-sensitivity troponin pathway.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.